Competitive Advantages

There are a number of clinical and product development advantages with small molecules as osteoinduction (OI) agents in bone graft substitutes.  Because small molecule compounds are amenable to synthetic chemistry, large compound libraries can be obtained with a range of suitable activities and properties.  Traditional medicinal chemistry can then be utilized to optimize the desired properties in a relatively short iterative development cycle.  Small molecules are less expensive to synthesize, more stable and amenable to a wide variety of formulations versus orthobiologics.  The cost differences are further magnified given the third-party relationships that exist for intellectual property and manufacturing rights to competitive OI biologics.  Perhaps most importantly, OssiFi's small molecule OI agents exhibit direct targeted effects and one of these agents, in combination with an osteoconductive scaffold matrix with a well-controlled release profile, should offer an additional safety advantage over competitive products.


Web Hosting Companies